[go: up one dir, main page]

MY142166A - Bioactive compound for reversal of obesity - Google Patents

Bioactive compound for reversal of obesity

Info

Publication number
MY142166A
MY142166A MYPI20052297A MY142166A MY 142166 A MY142166 A MY 142166A MY PI20052297 A MYPI20052297 A MY PI20052297A MY 142166 A MY142166 A MY 142166A
Authority
MY
Malaysia
Prior art keywords
obesity
bioactive compound
treatment
blood vessel
fat tissue
Prior art date
Application number
Inventor
Sazaly Abu Bakar
Original Assignee
Univ Malaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Malaya filed Critical Univ Malaya
Priority to MYPI20052297 priority Critical patent/MY142166A/en
Publication of MY142166A publication Critical patent/MY142166A/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

THE PRESENT INVENTION PROVIDES NEW USE AND PRODUCT FOR TREATMENT OF DISEASES AND DISEASE CONDITIONS. MORE PARTICULARLY, THE PRESENT INVENTION RELATES TO THE NEW USE OF BIOACTIVE COMPOUND DERIVED FROM THE EURYCOMA LONGIFOLIA JACK FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISEASES. THE BIOACTIVE COMPOUND COMPRISES QUASSINOID, 13(21)-EPOXYEURYCOMANONE. THIS BIOACTIVE COMPOUND POSSESSES ACTIVITY OF DOWN-REGULATING THE EXPRESSION OF SPECIFIC PROTEIN THAT IS OVER-EXPRESSED ON BLOOD VESSEL CELLS THAT SERVE ONLY WHITE FAT TISSUE BUT ABSENT ON BLOOD VESSEL CELLS OF OTHER TISSUES OR ORGANS. THEREFORE, THE BIOACTIVE COMPOUND HAS THE EFFECTS ON INHIBITION OR REDUCTION OF THE FORMATION OF BLOOD VESSELS IN WHITE FAT TISSUE AND EVENTUALLY REVERSES THE OBESITY AND EVENTUALLY OBESITY-RELATED DISEASES.
MYPI20052297 2005-05-20 2005-05-20 Bioactive compound for reversal of obesity MY142166A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI20052297 MY142166A (en) 2005-05-20 2005-05-20 Bioactive compound for reversal of obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20052297 MY142166A (en) 2005-05-20 2005-05-20 Bioactive compound for reversal of obesity

Publications (1)

Publication Number Publication Date
MY142166A true MY142166A (en) 2010-10-15

Family

ID=47320719

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20052297 MY142166A (en) 2005-05-20 2005-05-20 Bioactive compound for reversal of obesity

Country Status (1)

Country Link
MY (1) MY142166A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058737B2 (en) 2018-10-29 2021-07-13 Biotropics Malaysia Berhad Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058737B2 (en) 2018-10-29 2021-07-13 Biotropics Malaysia Berhad Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females

Similar Documents

Publication Publication Date Title
DE60236413D1 (en) INHIBITORS OF HMGB1 FOR THE TREATMENT OF TISSUE DISEASES
ATE372777T1 (en) USE OF NITRITE SALTS TO TREAT CARDIOVASCULAR DISEASES
ATE356607T1 (en) USE OF NATIVE ZEIN TO IMPROVE HAIR CONDITION AND REMEDIES
ATE373082T1 (en) PRE-ADIPOSE CELL LINES
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
Gabr et al. Oromandibular reconstruction with vascularized free flaps: A review of 50 cases
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
Laurant et al. Dietary magnesium intake can affect mechanical properties of rat carotid artery
MXPA05003818A (en) Gene expression profiling from ffpe samples.
AU2008271307A1 (en) New use of known pharmacologically active chemical compounds
Baiev et al. The economic determinants of the world medical tourism industry development
MY142166A (en) Bioactive compound for reversal of obesity
Lin et al. Vasorelaxing and antihypertensive activities of synthesized peptides derived from computer-aided simulation of pepsin hydrolysis of yam dioscorin
TW200741011A (en) Method for the diagnosis and treatment of cardiovascular diseases
WO2004044241A3 (en) Use of fish larvae as a screening model
Elbaz et al. Reconstruction of glossectomy defects post oncologic resection
Ahirwar et al. The prevalence of hypertension in Indian populations in last decade
Kazmi et al. Influence of sibutramine, orlistat and Ispaghula in reducing body weight and total body fat content in obese individuals
KR100637415B1 (en) Composition for the prevention and treatment of hypertension containing polypeptides having AC inhibitory activity as an active ingredient
DE50310383D1 (en) HUMAN CHONDROUSTEOMODULIN (TIG2), PREPARATION AND USE FOR THE TREATMENT OR DIAGNOSIS OF BONE AND TISSUE DISEASES, FAT SUPPORT AND INFLAMMATORY DISEASES AND SKIN DISEASES
SIMALCSIK et al. NECROPOLA NR. 2 DE LA PIETROASELE. DATE ARHEOLOGICE ȘI PALEOANTROPOLOGICE.
Parveen Protective Effect of Aabresham (Bombyx Mori) Against Atherosclerosis
Cheng et al. ACE Inhibitor-Induced Angioedema of the Small Bowel: 2140
WO2023003518A3 (en) Methods, compositions and kits for fat remodelling
Stone The Acupuncture Treatment of Panic Attacks